Replies to post #17849 on Sunshine Biopharma Inc (SBFM)

[BooDog]

I'm waiting to hear about everything that still needs to be done before phase I can even start. Not to mention following through on their plans to re domicile.

Follow through builds confidence.

Name the CRO when they get it. And reveal the space for their pharma unit. No secrets allowed.

“Engaging a CRO is the next step in our Adva-27a drug development program,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “We are delighted to have arrived at this advanced stage in the development of our Adva-27a. The CRO will compile the testing results conducted to date, follow and document the GMP manufacturing process, manage the large animal studies and file with the appropriate regulatory agencies for go-ahead with Phase I human trials.”

“In addition to the generic pharmaceutical business unit we are putting into place..."

[Angel21stCentury]

Sunshine Biopharma's Adva-27a Preclinical Research Results to Be Published in October Issue of ANTICANCER RESEARCH
MONTREAL--(Marketwire - Sep 25, 2012) - Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that its paper on Adva-27a preclinical research results has been accepted and will be published in the October issue of ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment.
Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal (Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology (http://ar.iiarjournals.org).
Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Cientifica (SIIC) Databases.